Hester Biosciences Q3 Results: Poultry Pharma ka Kamaal, PAT **140%** Bhaga!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
Hester Biosciences Q3 Results: Poultry Pharma ka Kamaal, PAT **140%** Bhaga!
Overview

Hester Biosciences ke Q3 results aa gaye hain, aur bhai log, picture thodi mixed hai! Poultry Healthcare mein toh zabardast tezi dikhi hai, par Animal Healthcare thoda piche reh gaya. Lekin sabse achhi khabar yeh hai ki company ka PAT (Profit After Tax) akele **140%** tak bhag gaya hai!

Aakhir hua kya Q3 mein?

Company ne Q3 FY26 mein standalonewise revenue mein 12% ka growth dikhaya hai, jo ₹135.5 crore tak pahunch gaya. Lekin asal game winner raha PAT, jo 140% jump karke ₹24.1 crore ho gaya! Yeh sab cost control aur product mix mein changes ki wajah se hua hai. Agar 9 mahine ki baat karein toh revenue 5% gira hai, par PAT 16% badha hai.

Consolidated basis par bhi revenue mein 22% ka badhotri hui hai, ₹170.1 crore tak pahunch gaya.

Kahan chal raha hai dum? Kahan lag raha hai break?

Poultry Healthcare is quarter ka asli hero raha! Is segment mein 32% YoY ka growth dekhne ko mila hai, primarily market mein penetration badhane aur ek naye H9N2 Avian Influenza vaccine ke license milne se. Ab company India mein iska manufacturing bhi karegi.

Doosri taraf, Animal Healthcare segment mein 38% ki badi girawat aayi hai. Iska reason govt ke immunization programs mein delays hai, jahan PPR aur goat pox vaccines ki delivery postpone ho gayi. Petcare segment abhi bhi chota hai, Animal Health revenue ka 5% se bhi kam.

Future ka plan kya hai?

Management ab tender-based business par dependence kam karna chahta hai. Unka focus ab exports aur commercial markets mein ghusne par hai. Company ne apni fill/finish facility ko upgrade bhi kiya hai, jisse drug product capacity double ho gayi hai. Unke paas ₹182 crore ka CWIP bhi hai jo aane wale months mein capitalize hoga.

Toh ab kya hoga?

Company ko Q4 FY26 se Animal Health mein recovery ki ummeed hai, par yeh govt programs ke timelines par depend karta hai. H9N2 vaccine ka rollout aur export markets mein growth par nazar rakhni hogi. Is quarter mein EBITDA roughly ₹20 crore raha hai, par asal focus YoY profitability improve karne par hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.